Skip to content
Lawsuit Help Desk

Lawsuit News Center

FDA’s Oversight of Xeljanz

In this article, we give a general summary of the FDA’s monitoring and oversight of Xeljanz in this post, covering the necessary testing and clinical studies, any warnings issued, findings attained, and other actions done, as well as any warnings.

Observation and Supervision

The drug Xeljanz is used to treat a number of autoimmune diseases. These conditions include ulcerative colitis and rheumatoid arthritis. Xeljanz underwent extensive research and clinical trials to make sure it was safe and effective for use in patients, much like all new medications that sought FDA clearance. However, serious safety risks have been uncovered.

Mandatory Testing

Like any new drug, Xeljanz was required to must pass multiple stages of testing to show that it is both safe and effective before the FDA was willing to approve it. These phases for Xeljanz included three phases of human clinical trials as well as preclinical research on animals.

The purpose of the clinical studies for Xeljanz, which involved thousands of patients, was to assess the drug’s safety and efficacy at various doses and in various patient populations. Trials evaluated potential adverse effects and medication interactions as well.

Mandatory Clinical Trials

There were three stages of the Xeljanz clinical trials: Phase 1: To ascertain the drug’s safety and pharmacokinetics, a small group of healthy volunteers were administered various doses of the medication. Phase 2: More patients with the targeted autoimmune condition were involved in this phase. This phase’s objective was to assess the drug’s efficacy and safety at various dosages. Phase 3: Patients with the specific autoimmune condition were involved in even bigger groups in this phase. This phase’s objective was to confirm the medication’s efficacy and safety over a larger patient base.

Warnings are given

The FDA issued many safety-related warnings following the approval of Xeljanz. The FDA issued a warning in February 2019 regarding an elevated risk of blood clots and fatalities in individuals taking higher dosages of Xeljanz. Because to this caution, the drug’s label was altered to add a black box warning concerning the elevated risk of blood clots.

The FDA again issued a warning in July 2021 regarding individuals on Xeljanz at a dose of 10 mg twice daily having an elevated risk of fatal heart-related events, cancer, and other adverse events. The FDA advised using Xeljanz at the lowest effective dose in all patients and not prescribing it to people who had specific underlying illnesses, such as heart disease.

Additional Steps Taken

The FDA has taken further measures in relation to Xeljanz in addition to the warnings that it has published. For instance, the FDA mandated that Pfizer carry out a post-marketing study to further assess the hazards connected to the medication. This investigation is still underway and will offer further information regarding the security of Xeljanz in practical situations. Also, the FDA mandates that Pfizer continuously monitor Xeljanz’s safety and notify the organization of any fresh safety concerns. This monitoring is meant to address drug safety concerns and ensure issues are found and resolved quickly.

Takeaways

Due to the serious potential complications of certain autoimmune disorders, doctors have been authorized to keep prescribing Xeljanz despite its associated risks. Clinical trials have proven beneficial results in terms of symptom relief and quality of life improvement for people afflicted with a variety of conditions. As such, healthcare practitioners must ensure that patients are aware of the dangers linked to this particular medication while also using the lowest effective dosage. Furthermore, all patients taking Xeljanz should be closely monitored for signs of blood clots, heart-related incidents or any other adverse reactions.

The large number of lawsuits filed for blood clots and heart conditions from Xeljanz usage is indicative of the life-threatening implications of its usage.